Head-to-head · free
LB Pharmaceuticals vs Lexeo Therapeutics, Inc. Common Stock
LBRX vs LXEO — return on capital, cash generation, margins and balance sheet side by side.
LBRX
2 / 3
measures where LBRX leads
LXEO
1 / 3
measures where LXEO leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | LBRX · FY2025 | LXEO · FY2025 |
|---|---|---|
| Revenue | — | — |
| Net income | (25.2M) | (100.0M) |
| Revenue growth (yearly, multi-year) | — | — |
| Free cash flow | (35.3M) | (99.0M) |
| Free cash flow margin | — | — |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | — | -55.0% |
| Gross margin | — | — |
| Operating margin | — | — |
| Net debt / EBITDA | 8.32x | 0.59x |
Figures are as reported by each company; latest fiscal year shown.
Where LB Pharmaceuticals's cash went (FY2025)
- Capital spending
- $52000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Lexeo Therapeutics, Inc. Common Stock's cash went (FY2025)
- Capital spending
- $397000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free